.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VENTURE trial evaluated dupilumab in patients with severe asthma who were dependent on systemic glucocorticoids. Participants received dupilumab or placebo while undergoing a structured reduction in their maintenance oral corticosteroid dose. Dupilumab allowed a significantly greater reduction in daily steroid exposure while also improving asthma control and reducing severe exacerbations in this high-risk population. The study is clinically important because chronic oral corticosteroid exposure carries substantial cumulative toxicity, so a treatment that can reduce steroid dependence has value beyond symptom improvement alone. For HCPs, the key message is to recognize steroid-dependent disease as a marker of severe asthma requiring specialist-level assessment. Before escalating to a biologic, clinicians should confirm adherence, inhaler technique, phenotype, comorbidities, and the accuracy of the asthma diagnosis. Once those foundations are in place, biologic therapy can be used strategically to reduce steroid burden and exacerbation risk. The findings fit the conference’s severe-asthma debate and its emphasis on phenotyping and modern biologic therapy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VENTURE trial evaluated dupilumab in patients with severe asthma who were dependent on systemic glucocorticoids. Participants received dupilumab or placebo while undergoing a structured reduction in their maintenance oral corticosteroid dose. Dupilumab allowed a significantly greater reduction in daily steroid exposure while also improving asthma control and reducing severe exacerbations in this high-risk population. The study is clinically important because chronic oral corticosteroid exposure carries substantial cumulative toxicity, so a treatment that can reduce steroid dependence has value beyond symptom improvement alone. For HCPs, the key message is to recognize steroid-dependent disease as a marker of severe asthma requiring specialist-level assessment. Before escalating to a biologic, clinicians should confirm adherence, inhaler technique, phenotype, comorbidities, and the accuracy of the asthma diagnosis. Once those foundations are in place, biologic therapy can be used strategically to reduce steroid burden and exacerbation risk. The findings fit the conference’s severe-asthma debate and its emphasis on phenotyping and modern biologic therapy.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
